A detailed history of Nisa Investment Advisors, LLC transactions in Cerus Corp stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 921 shares of CERS stock, worth $1,584. This represents 0.0% of its overall portfolio holdings.

Number of Shares
921
Previous 375 145.6%
Holding current value
$1,584
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$1.7 - $2.39 $928 - $1,304
546 Added 145.6%
921 $1,000
Q2 2024

Jul 19, 2024

BUY
$1.62 - $2.04 $53 - $67
33 Added 9.65%
375 $0
Q1 2024

May 01, 2024

BUY
$1.66 - $2.42 $166 - $242
100 Added 41.32%
342 $0
Q4 2023

Jan 25, 2024

BUY
$1.25 - $2.35 $302 - $568
242 New
242 $0
Q2 2023

Aug 11, 2023

BUY
$1.79 - $2.9 $6,343 - $10,277
3,544 Added 55.47%
9,933 $24,000
Q1 2023

May 02, 2023

BUY
$2.65 - $3.81 $16,483 - $23,698
6,220 Added 3680.47%
6,389 $19,000
Q3 2022

Nov 07, 2022

SELL
$3.43 - $5.83 $16,570 - $28,164
-4,831 Reduced 96.62%
169 $1,000
Q2 2022

Aug 03, 2022

SELL
$4.41 - $5.69 $17,772 - $22,930
-4,030 Reduced 44.63%
5,000 $26,000
Q1 2022

Apr 29, 2022

SELL
$4.81 - $6.99 $4,858 - $7,059
-1,010 Reduced 10.06%
9,030 $50,000
Q4 2021

Feb 03, 2022

BUY
$5.97 - $7.93 $39,103 - $51,941
6,550 Added 187.68%
10,040 $54,000
Q2 2021

Aug 06, 2021

SELL
$5.35 - $6.35 $50,022 - $59,372
-9,350 Reduced 72.82%
3,490 $21,000
Q4 2020

Jan 25, 2021

BUY
$5.25 - $8.56 $19,162 - $31,244
3,650 Added 39.72%
12,840 $89,000
Q3 2020

Oct 20, 2020

BUY
$5.78 - $7.47 $42,020 - $54,306
7,270 Added 378.65%
9,190 $58,000
Q3 2019

Oct 17, 2019

BUY
$4.86 - $6.05 $4,228 - $5,263
870 Added 82.86%
1,920 $10,000
Q3 2018

Oct 16, 2018

BUY
$6.89 - $7.78 $7,234 - $8,169
1,050 New
1,050 $8,000

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $305M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.